Bayer announced the acquisition of two investigational pan-amyloid molecular imaging agents — AT-01 (124-Iodine-evuzamitide) and AT-05 (PAR-Peptide + technetium-99m) — from clinical-stage biopharmaceutical company Attralus, strengthening the company’s entry into diagnostic tracers and advancing its precision cardiology strategy.
AT-01, a PET tracer now in Phase III development, uses an amyloid-binding peptide labelled with iodine-124 to detect systemic amyloid deposits across organs including the heart, kidney, liver and spleen. It is the first pan-amyloid imaging agent to receive Breakthrough Therapy Designation from the U.S. FDA for cardiac amyloidosis and also holds orphan drug status in the U.S. and EU. The Phase III REVEAL study has completed dosing.
AT-05 is a SPECT tracer currently in Phase I, designed to broaden diagnostic access by using technetium-99m imaging technology that is widely available in nuclear medicine settings.
The acquisition positions Bayer to address persistent under diagnosis of systemic and cardiac amyloidosis, a group of conditions that can lead to heart failure and affect an estimated 400,000 people globally, by providing more sensitive and earlier detection at the molecular level. Earlier and accurate diagnosis is increasingly important as targeted therapies for amyloidosis advance.
Financial terms of the transaction were not disclosed. Attralus will retain focus on its therapeutic pipeline, including AT-02 in Phase II and next-generation pan-amyloid removal candidates in preclinical development.
The deal builds on Bayer’s radiology franchise, which generated €2.1 billion in sales in 2024, and on a global radio-diagnostic tracer market valued at roughly $3 billion in 2024. By adding PET and SPECT tracers to its portfolio, Bayer aims to integrate diagnostic tracers with its existing imaging products and fluid-delivery devices to offer more comprehensive molecular imaging solutions.
Regulatory and commercial timelines will depend on Bayer’s continued clinical development and approvals for AT-01 and AT-05. If successful, the tracers could expand clinician ability to detect and monitor amyloid disease earlier and more accurately, supporting timely treatment decisions and improved patient management.
